Knight Therapeutics Inc. (GUD : TSX)
Common Stock
$9.76
CAD
+0.01 (0.10%)
Last updated: 2026-08-26
Get GUD alerts:
GUD
Knight Therapeutics Inc.
WealthAwesomePerformance
1 Day
+0.10%
1 Week
-0.61%
1 Month
-0.61%
YTD
+65.14%
Key Statistics
Market Cap
$957.76M
52W High
$10.17
52W Low
$5.66
P/E Ratio
65.00
50 Day MA
$9.63
200 Day MA
$7.48
Beta
0.05
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 8/26/2026 | $9.47 | $9.80 | $9.47 | $9.76 | $9.76 | 42,353 |
| 8/25/2026 | $9.67 | $9.91 | $9.67 | $9.75 | $9.75 | 82,012 |
| 8/24/2026 | $9.66 | $9.83 | $9.38 | $9.66 | $9.66 | 91,189 |
| 8/21/2026 | $9.70 | $9.74 | $9.61 | $9.66 | $9.66 | 39,066 |
| 8/20/2026 | $9.84 | $9.93 | $9.63 | $9.63 | $9.63 | 53,520 |
| 8/19/2026 | $9.73 | $9.89 | $9.69 | $9.82 | $9.82 | 54,952 |
| 8/18/2026 | $9.75 | $9.80 | $9.61 | $9.73 | $9.73 | 53,259 |
| 8/17/2026 | $9.34 | $9.80 | $9.30 | $9.78 | $9.78 | 95,971 |
| 8/14/2026 | $9.21 | $9.32 | $9.20 | $9.32 | $9.32 | 122,185 |
| 8/13/2026 | $9.34 | $9.34 | $9.20 | $9.21 | $9.21 | 51,669 |
Analyst Price Targets
Based on analyst covering GUD
Wall Street analysts forecast GUD stock price to rise 14.6% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$11.19
+14.6% Upside
Current Price
C$9.76
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
32.3%
Annualized
90-Day Vol
32.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$11.67
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$10.36 | C$9.27 – C$11.58 |
| 60 trading days | C$10.99 | C$9.39 – C$12.87 |
| 90 trading days | C$11.67 | C$9.62 – C$14.15 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Knight Therapeutics Inc.
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.
Financials
- Revenue (TTM)
- $547.31M
- EBITDA
- $81.16M
- Profit Margin
- 2.72%
- ROE (TTM)
- 1.91%
- EPS (Diluted)
- 0.15
- Book Value
- 8.13
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About GUD
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| BNG | Bengal Energy Ltd | $0.03 | +25.00% |
| KRN | Karnalyte Resources Inc. | $0.32 | +10.34% |
| FRX | Fennec Pharmaceuticals Inc | $17.00 | +9.75% |
| BCT | Briacell Therapeutics Corp | $5.62 | +9.34% |
| YRB | Yorbeau Resources Inc | $0.06 | +9.09% |
| PRU | Perseus Mining Ltd | $6.58 | +7.69% |
| CRDL | Cardiol Therapeutics Inc Class A | $2.97 | +7.61% |
| SLT | Saltire Capital Ltd. | $2.70 | +7.57% |
GUD.TO news timeline
15 articles covering GUD.TO, most recent first
LatestWhat's Going On With Knight Therapeutics Inc. Stock Thursday?
August 2026
- What's Going On With Knight Therapeutics Inc. Stock Thursday?
- Why Knight Therapeutics Inc. stock is tanking today
- What's Going On With Knight Therapeutics Inc. Stock Thursday?
- Why Knight Therapeutics Inc. stock fell yesterday
- Why Knight Therapeutics Inc. stock fell yesterday
- Knight Therapeutics Inc. GUD Earnings Miss Estimates by 188.0%
- What's Going On With Knight Therapeutics Inc. Stock Thursday?
- Why Knight Therapeutics Inc. stock is rising today